{
    "clinical_study": {
        "@rank": "58977", 
        "arm_group": [
            {
                "arm_group_label": "AMG 073", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This 6 month long study will assess an investigational medication for patients on dialysis\n      with secondary hyperparathyroidism.  The study will look at the effects on parathyroid\n      hormone, calcium and phosphorus levels."
        }, 
        "brief_title": "A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients", 
        "completion_date": {
            "#text": "March 2003", 
            "@type": "Actual"
        }, 
        "condition": [
            "Secondary Hyperparathyroidism", 
            "End Stage Renal Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hyperparathyroidism", 
                "Hyperparathyroidism, Secondary", 
                "Kidney Diseases", 
                "Kidney Failure, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "-  Patients must be receiving hemodialysis; * Have elevated parathyroid hormone levels;\n             * Not be pregnant or nursing; and * Not have had a heart attack in the last 3 months."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 17, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00037635", 
            "org_study_id": "20000172"
        }, 
        "intervention": [
            {
                "arm_group_label": "AMG 073", 
                "description": "30 mg QD orally 60 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally", 
                "intervention_name": "AMG 073", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "placebo", 
                "description": "30 mg QD orally 60 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Calcimimetic Agents"
        }, 
        "lastchanged_date": "May 6, 2013", 
        "link": {
            "description": "AmgenTrials clinical trials website", 
            "url": "http://www.amgentrials.com"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 3 Study to Assess the Efficacy and Safety of an Oral Calcimimetic Agent (AMG 073) in Secondary Hyperparathyroidism of End Stage Renal Disease Treated With Hemodialysis", 
        "overall_official": {
            "affiliation": "Amgen", 
            "last_name": "MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2003", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "To evaluate the efficacy of AMG 073 compared with placebo by determining the proportion of subjects with a mean intact parathyroid hormone (iPTH) value <= 250 pg/mL (26.5 pmol/L) during the efficacy assessment phase.", 
            "safety_issue": "No", 
            "time_frame": "efficacy assessment phase (last 14 weeks of treatment)"
        }, 
        "removed_countries": {
            "country": "United States"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00037635"
        }, 
        "responsible_party": {
            "name_title": "Global Development Leader", 
            "organization": "Amgen Inc."
        }, 
        "results_reference": {
            "PMID": "16105056", 
            "citation": "Martin KJ, Juppner H, Sherrard DJ, Goodman WG, Kaplan MR, Nassar G, Campbell P, Curzi M, Charytan C, McCary LC, Guo MD, Turner SA, Bushinsky DA. First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl. Kidney Int. 2005 Sep;68(3):1236-43."
        }, 
        "secondary_outcome": [
            {
                "measure": "To evaluate the efficacy of AMG 073 compared with placebo by determining:  percentage change from baseline in mean calcium x phosphorus product (Ca x P) during the efficacy assessment phase", 
                "safety_issue": "No", 
                "time_frame": "efficacy assessment phase (last 14 weeks of treatment)"
            }, 
            {
                "measure": "To evaluate the efficacy of AMG 073 compared with placebo by determining:  changes in self-reported cognitive function from baseline to the end of the efficacy assessment phase", 
                "safety_issue": "No", 
                "time_frame": "efficacy assessment phase (last 14 weeks of treatment)"
            }, 
            {
                "measure": "To evaluate the safety of AMG 073 compared with placebo.", 
                "safety_issue": "Yes", 
                "time_frame": "entire study"
            }
        ], 
        "source": "Amgen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Amgen", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2001", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }, 
    "geocoordinates": {}
}